SCHEMBL12377802

SCHEMBL12377802

CSc1nnc(-c2cccc(C)c2)o1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 6/20 0.67
NPC1 O15118 5/20 0.65
RAB9A P51151 5/20 0.65
SMN1; SMN2 Q16637 4/20 0.65
TSHR P16473 1/20 0.65
CYP1A2 P05177 1/20 0.63
CYP2C9 P11712 1/20 0.63
CYP2C19 P33261 1/20 0.63
L3MBTL1 Q9Y468 1/20 0.63
MAPT P10636 4/20 0.59
THRB P10828 1/20 0.59
ALDH1A1 P00352 4/20 0.58
TP53 P04637 2/20 0.58
POLB P06746 1/20 0.58
HSD17B10 Q99714 1/20 0.58
GAA P10253 1/20 0.54
MAPK1 P28482 1/20 0.54
KDM4E B2RXH2 2/20 0.51
CA1 P00915 1/20 0.51
CA2 P00918 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11674120 0.84 SMN1; SMN2 (0.89) HPGDNPC1RAB9ASMN1; SMN2TSHR
SCHEMBL13882293 0.82 SMN1; SMN2 (0.85) HPGDNPC1RAB9ASMN1; SMN2TSHR
SCHEMBL408382 0.80 HPGD (1.00) HPGDNPC1RAB9ASMN1; SMN2L3MBTL1
SCHEMBL16675211 0.80 SMN1; SMN2 (0.82) HPGDNPC1RAB9ASMN1; SMN2TSHR
SCHEMBL20221777 0.79 HPGD (0.70) HPGDNPC1RAB9ASMN1; SMN2TSHR
SCHEMBL12974 0.79 HPGD (0.73) HPGDNPC1RAB9ASMN1; SMN2TSHR
SCHEMBL16157024 0.78 NPC1 (1.00) HPGDNPC1RAB9ASMN1; SMN2TSHR
SCHEMBL12634931 0.77 NPC1 (0.83) HPGDNPC1RAB9ASMN1; SMN2TSHR
SCHEMBL17068794 0.77 MAPT (0.77) HPGDNPC1RAB9ASMN1; SMN2TSHR
SCHEMBL17068756 0.77 MAPT (0.70) HPGDNPC1RAB9ASMN1; SMN2CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7998954-B2 Pyrimidodiazepinone derivative KYOWA HAKKO KIRIN CO., LTD. (JP) 2011-08-16 US disclosed
US-7998954-B2 Pyrimidodiazepinone derivative KYOWA HAKKO KIRIN CO., LTD. (JP) 2011-08-16 US disclosed
US-20100190775-A1 PYRIMIDODIAZEPINONE DERIVATIVE KYOWA HAKKO KIRIN CO., LTD (JP) 2010-07-29 US disclosed
US-20100190775-A1 PYRIMIDODIAZEPINONE DERIVATIVE KYOWA HAKKO KIRIN CO., LTD (JP) 2010-07-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100190775-A1 PYRIMIDODIAZEPINONE DERIVATIVE KCNJ1, KCNJ11, ADRA1D HPGD 864/4885NPC1 1132/4885RAB9A 2645/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.